Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - rosuvastatin calcium -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - rosuvastatin calcium -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - rosuvastatin calcium -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - rosuvastatin calcium -

United States - English - NLM (National Library of Medicine)

tris pharma inc - rosuvastatin calcium (unii: 83mvu38m7q) (rosuvastatin - unii:413kh5zj73) - rosuvastatin 5 mg - rosuvastatin calcium tablets is indicated: - to reduce the risk of stroke, myocardial infarction, and arterial revascularization procedures in adults without established coronary heart disease who are at increased risk of cardiovascular (cv) disease based on age, hscrp ≥2 mg/l, and at least one additional cv risk factor. - as an adjunct to diet to: - reduce ldl-c in adults with primary hyperlipidemia. - reduce low-density lipoprotein cholesterol (ldl-c) and slow the progression of atherosclerosis in adults. - reduce ldl-c in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (hefh).as an adjunct to other ldl-c-lowering therapies, or alone if such treatments are unavailable, to reduce ldl-c in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (hofh). - as an adjunct to diet for the treatment of adults with: - primary dysbetalipoproteinemia. - hypertriglyceridemia. rosuvastatin calcium tablets is contraindicated i

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - rosuvastatin calcium -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - rosuvastatin calcium -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - rosuvastatin calcium -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - rosuvastatin calcium -

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - rosuvastatin calcium (unii: 83mvu38m7q) (rosuvastatin - unii:413kh5zj73) - pediatric use information for patients 7 to 17 years of age is approved for astrazeneca's crestor (rosuvastatin calcium) tablets. however, due to astrazeneca's marketing exclusivity rights, this drug product is not labeled with that pediatric information. rosuvastatin calcium tablets are indicated as adjunctive therapy to diet for the treatment of adult patients with hypertriglyceridemia.  rosuvastatin calcium tablets are indicated as an adjunct to diet for the treatment of adult patients with primary dysbetalipoproteinemia (type iii hyperlipoproteinemia). rosuvastatin calcium tablets are indicated as adjunctive therapy to other lipid-lowering treatments (e.g., ldl apheresis) or alone if such treatments are unavailable to reduce ldl-c, total-c, and apob in adult patients with homozygous familial hypercholesterolemia. rosuvastatin calcium tablets have not been studied in fredrickson type i and v dyslipidemias. rosuvastatin is contraindicated in the following conditions: - patients with a known hypersensitivity